Together, our data support MED1 as a major player in breast cancer resistance to both HER2- and ER-targeted therapies, and that MED1 and its target genes, such as Jab1, could represent promising targets to overcome the resistance of HER2+/ER+ tumors to these therapies. This evidence concerns the gene ERBB2 and breast carcinoma.